Publications by authors named "Antti Siljander"
Article Synopsis
- The DEBUT trial aimed to determine if percutaneous coronary intervention (PCI) using drug-coated balloons is as effective as using bare-metal stents in patients at high risk for bleeding.
- Conducted in Finland, the trial included 220 patients who were randomly assigned to receive either a drug-coated balloon or a bare-metal stent after successful lesion predilation.
- Results showed that at 9 months, only 1% of patients in the drug-coated balloon group experienced major adverse cardiac events compared to 14% in the bare-metal stent group, indicating that drug-coated balloons were significantly better for this patient population.
Objectives: The aim of this single center all-comers retrospective registry study was to assess the efficacy and safety of percutaneous coronary intervention (PCI) using drug-coated balloon (DCB) in de novo lesions including large proximal coronary arteries.
Methods: A total of 487 PCIs were performed using paclitaxel-coated DCB in 562 de novo lesions with the possibility for bailout stenting in a patient population presenting with stable coronary artery disease (CAD) or acute coronary syndrome (ACS). Half of the patients had at least one risk factor for bleeding.
Background: The MANTA system is a novel vascular closure device (VCD) and its safety and efficacy were compared to the ProGlide VCD in patients undergoing transfemoral transcatheter aortic valve implantation (TAVI).
Methods: This is a retrospective study including 222 patients who underwent transfemoral TAVI at three Finnish University Hospitals. The MANTA VCD was used in 107 patients and their outcome was compared with that of 115 patients in whom the arterial access was closed with the ProGlide VCD.
Aims: Life-threatening complications occur during transcatheter aortic valve implantation (TAVI) which can require emergent cardiac surgery (ECS). Risks and outcomes of patients needing ECS during or immediately after TAVI are still unclear.
Methods And Results: Incidence, risk factors, management, and outcomes of patients requiring ECS during transfemoral (TF)-TAVI were analysed from a contemporary real-world multicentre registry.
Objectives: We investigated the safety and efficacy of PCI using drug-coated balloon (DCB) after rotational atherectomy (rotablation) in a retrospective single center study in patients with calcified de novo coronary lesions. The majority of patients had an increased risk for bleeding.
Background: DCB has been effective in the treatment of in-stent restenosis, small vessels, and bifurcations.